Jason Allen, MD
Interventional Cardiology · Iowa City, IANPI 1225471816
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.8%), food and beverage and grants — rather than concentrated in one kind of arrangement. Medtronic accounts for 66.6% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $15,013, more than ten times the $404 reported in 2019.
Across 277 payments — averaging $106.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Edwards Lifesciences$2K
- Cardiovascular Systems Inc.$2K
- Boston Scientific$1K
- Abbott$746
- Maquet Cardiovascular L.L.C.$440
- plus $4K from 30 others
What the payments were for
- Consulting fees$4401%
- Grants$3,75013%
- Travel & lodging$16,20155%
- Food & beverage$8,76530%
- Education$4291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 55 | $19,702 |
| Edwards Lifesciences | 15 | $2,147 |
| Cardiovascular Systems Inc. | 12 | $1,643 |
| Boston Scientific | 39 | $1,234 |
| Abbott | 13 | $746 |
| Maquet Cardiovascular L.L.C. | 1 | $440 |
| Abiomed | 13 | $433 |
| Medical Device Business Services, Inc. | 5 | $398 |
| E.r. Squibb & Sons, L.L.C. | 24 | $338 |
| W. L. Gore & Associates, Inc. | 3 | $283 |
| Johnson & Johnson | 13 | $253 |
| Pfizer | 15 | $240 |
| Philips North America LLC | 3 | $224 |
| Shockwave Medical, Inc | 5 | $209 |
| Novartis | 12 | $186 |
| AstraZeneca | 8 | $175 |
| Acist Medical Systems, Inc. | 2 | $166 |
| Asahi Intecc USA, Inc. | 1 | $107 |
| Bayer | 4 | $86 |
| Boehringer Ingelheim | 4 | $65 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Amgen | 3 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $50 |
| Itamar Medical Inc | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Merck | 3 | $37 |
| Lantheus Medical Imaging, Inc. | 2 | $32 |
| Elutia, Inc. | 2 | $29 |
| Angiodynamics, Inc. | 1 | $28 |
| Cardiva Medical, Inc. | 1 | $27 |
| Heartflow, Inc. | 1 | $26 |
| Stryker | 1 | $21 |
| Novo Nordisk | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$14,434
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,720
- Diamondback Coronary$1,370
- HLS Set$440
- Carto 3$333
- Resolute$290
- GENERAL - STENTS$275
- Ensite Cardiac Mapping System$140
- Optis Coronary Imaging System$134
- Rhythmia Mapping System$132
- CVI SYSTEMS$122
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$122
- (6574) Coronary Other$116
- Mitra Clip system$112
- WATCHMAN FLX$110
- ASAHI PTCA Guide Wire$107
- GORE CARDIOFORM Septal Occluder$107
- Coronary Orbital Atherectomy System$105
How this compares
$29,584 in reported general payments places this provider in the 85th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $63,686 |
| JardianceEmpagliflozin | 11 | $20,017 |
| Metoprolol Succinate | 100 | $1,339 |
| Atorvastatin Calcium | 105 | $1,044 |
| Rosuvastatin Calcium | 32 | $714 |
| ClopidogrelClopidogrel Bisulfate | 66 | $604 |
| Losartan Potassium | 64 | $504 |
| Amlodipine Besylate | 93 | $433 |
| Carvedilol | 57 | $350 |
| Potassium Chloride | 26 | $314 |
| Atenolol | 30 | $305 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $290 |
| Lisinopril | 40 | $214 |
| Furosemide | 52 | $165 |
| Metoprolol Tartrate | 36 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $240 | $63,68662 claims |
| Boehringer IngelheimJardiance | $65 | $20,01711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Iowa City
- Hossein OuranosIowa City$28K
- Spas KotevIowa City$12K
- Waqas SiddiquiIowa City$10K
- Hisham IbrahimIowa City$8K
- Yehia SalehIowa City$6K
- James RossenIowa City$5K
- Connor YoungIowa City$4K
- Vikram SharmaIowa City$3K
- Phillip HorwitzIowa City$3K
- Ahmad ArhamIowa City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.